Nektar Shares Slide as Jury Weighs Lilly Lawsuit Over Rezpeg
Investors are watching liability and damages in Nektar’s breach case against Lilly, a key swing factor for the Rezpeg program. Analysts still see damages as the hard issue.
Investors are watching liability and damages in Nektar’s breach case against Lilly, a key swing factor for the Rezpeg program. Analysts still see damages as the hard issue.
Truist calls Vertex’s Phase 2b inaxaplin data a validation of APOL1 inhibition in AMKD and sees a 100,000+ extra patient opportunity, plus positive readthrough for Maze.
FDA posted Galleri briefing papers with no leftover lab-test questions. Panel meets Sept. 23; approval odds remain in focus.
Qiagen reviews options with Goldman and Moelis.
J&J is in talks to sell DePuy Synthes, its $9.3B hip-and-knee unit, to Apollo for about $20B. A deal could close in weeks—or J&J may spin it off.
GE HealthCare is considering a deal worth up to $1 billion for Sofie Biosciences, which makes radiopharmaceuticals used in cancer PET scans.